CQVA149A3401 Open Label Study of NVA237 or QVA149 in moderate COPD
Research type
Research Study
Full title
A prospective, multicentre, 12-week, randomised open-label study to evaluate the efficacy and safety of glycopyrronium (50 micrograms od) or indacaterol maleate and glycopyrronium bromide fixed-dose combination (110/50 micrograms od) regarding symptoms and health status in patients with moderate chronic obstructive pulmonary disease (COPD) switching from treatment with any standard COPD regimen.
IRAS ID
138102
Contact name
F Jaafar
Contact email
Sponsor organisation
Novartis Pharma Services AG
Eudract number
2013-003127-11
ISRCTN Number
n/a
Clinicaltrials.gov Identifier
n/a
REC name
East Midlands - Nottingham 2 Research Ethics Committee
REC reference
14/EM/0077
Date of REC Opinion
25 Mar 2014
REC opinion
Further Information Favourable Opinion